Jasper Therapeutics, Inc. (JSPR)

$2.22

+0.13 (+6.22%)
Rating:
Recommendation:
-
Symbol JSPR
Price $2.22
Beta 0.757
Volume Avg. 0.03M
Market Cap 84.085M
Shares () -
52 Week Range 1.73-18.88
1y Target Est -
DCF Unlevered JSPR DCF ->
DCF Levered JSPR LDCF ->
ROE -26.34% Sell
ROA -17.68% Sell
Operating Margin -
Debt / Equity 18.27% Neutral
P/E -
P/B 0.16 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest JSPR news


Healthcare
Biotechnology
NASDAQ Capital Market

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.